Molecule News and Research

RSS

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Researchers find connection between eye disease and arginase

Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

The discovery provides insight into a protein, renin, that is important in blood pressure regulation, and reveals the cause of one type of inherited kidney disease occurring in adults and children, said co-investigator Anthony Bleyer, M.D., professor of internal medicine-nephrology at the School of Medicine.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.

19 Aug 2009

New understanding on meningitis cause

A specific protein on the surface of a common bacterial pathogen allows the bacteria to leave the bloodstream and enter the brain, initiating the deadly infection known as meningitis. The new finding, which may guide development of improved vaccines to protect those most vulnerable, including young infants and the elderly, is now available online in the Journal of Experimental Medicine.

19 Aug 2009

Discovery of key factor that stimulates brain cancer cells to spread

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). In a move toward therapy, the researchers showed that a small designer protein can block this activity and reduce the spreading of GBM cells grown in the laboratory.

19 Aug 2009

Custom-tailored anti-cancer drugs

Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.

19 Aug 2009

Amira Pharmaceuticals submits IND for inflammatory and allergic disease treatment candidate

Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Food and Drug Administration.

19 Aug 2009

New colon cancer target

New research led by scientists at the University of North Carolina at Chapel Hill School of Medicine have found a drug target that suggests a potent way to kill colon cancers that resist current drugs aimed at blocking a molecule found on the surface of cells.

18 Aug 2009

Prion found to be a biomarker for pancreatic cancer

Mad cow disease is caused by the accumulation of an abnormal protein, the prion, in the brain of an affected patient. Outside of the brain, very little is known about prions.

18 Aug 2009

Molecules wrestle for supremacy to dictate the physical state of superstructures

Research at the University of Liverpool has found how mirror-image molecules gain control over each other and dictate the physical state of superstructures.

13 Aug 2009

Marijuana/Cannabis may protect against osteoporosis

Scientists investigating the effects of cannabis on bone health have found that its impact varies dramatically with age.

13 Aug 2009

Drug design: palladium catalyst used to attach fluorine atom to aromatic compounds

A team of MIT chemists has devised a new way to add fluorine to a variety of compounds used in many drugs and agricultural chemicals, an advance that could offer more flexibility and potential cost-savings in designing new drugs.

13 Aug 2009

Pacific Biosciences raises additional $68 million in financing

Pacific Biosciences, a private company pioneering the development of a transformative DNA sequencing technology, announced today it has raised an additional $68 million in financing.

12 Aug 2009

New understanding of role hyaluronic acid in skeletal growth

Investigators at Burnham Institute for Medical Research (Burnham) and the University of Connecticut Health Center (U.C.H.C.) have gained new understanding of the role hyaluronic acid (HA) plays in skeletal growth, chondrocyte maturation and joint formation in developing limbs.

12 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

Toxic levels of Alzheimer's clusters in brain determined

Scientists have long suspected that Alzheimer's disease (AD) is caused by a small protein called the amyloid β-protein (Aβ). This protein clumps or binds to itself, eventually changing chemically to create brain protein deposits (plaques) that are characteristic of AD.

11 Aug 2009

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Upstream Biosciences Inc. (OTCBB: UPBS) has announced that the company is actively seeking licensors or acquirers for its novel anti-parasitic drug discovery portfolio and cancer diagnostic platform.

11 Aug 2009

Molecule News and Research

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Researchers find connection between eye disease and arginase

CEL-SCI expands work on current H1N1 virus vaccine

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

New understanding on meningitis cause

Discovery of key factor that stimulates brain cancer cells to spread

Custom-tailored anti-cancer drugs

Amira Pharmaceuticals submits IND for inflammatory and allergic disease treatment candidate

New colon cancer target

Prion found to be a biomarker for pancreatic cancer

Molecules wrestle for supremacy to dictate the physical state of superstructures

Marijuana/Cannabis may protect against osteoporosis

Drug design: palladium catalyst used to attach fluorine atom to aromatic compounds

Pacific Biosciences raises additional $68 million in financing

New understanding of role hyaluronic acid in skeletal growth

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Toxic levels of Alzheimer's clusters in brain determined

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News